| AD | Alzheimer’s disease |
| AIF | Apoptosis-inducing factor |
| AMPA | α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid |
| AMPARs | AMPA receptors |
| BBB | Blood–brain barrier |
| CBF | Cerebral blood flow |
| CBP | CREB-binding protein |
| CNS | Central nervous system |
| DOX | Doxorubicin |
| EAAT/EAATs | Excitatory amino acid transporter(s) |
| EAE | Experimental autoimmune encephalomyelitis |
| GAPDH | Glyceraldehyde-3-phosphate dehydrogenase |
| GBMs | Graphene-based materials |
| GO | Graphene oxide |
| GQDs | Graphene quantum dots |
| HCs | Hemichannels |
| HD | Huntington’s disease |
| IP3 | Inositol triphosphate |
| KA | Kainic acid |
| KARs | Kainate receptors |
| MEAs | Microelectrode arrays |
| mHTT | Mutant huntingtin |
| NCE | Na+/Ca2+ exchanger |
| NMDA | N-methyl-d-aspartate |
| NMDAR/NMDARs | NMDA receptor(s) |
| NO | Nitric oxide |
| NOS | Nitric oxide synthase |
| OGD | Oxygen–glucose deprivation |
| ONOO− | Peroxynitrite |
| PAR | Poly(ADP-ribose) |
| PARP | Poly(ADP-ribose) polymerase |
| PD | Parkinson’s disease |
| PID | Peri-infarct depolarization |
| PLC | Phospholipase C |
| PSD/PSD95 | Postsynaptic density/Postsynaptic density protein 95 |
| ROS | Reactive oxygen species |
| SNpc | Substantia nigra pars compacta |
| VGCCs | Voltage-gated calcium channels |
| VGSCs | Voltage-gated sodium channels |